' Compelling ' Data on New Agent in Pretreated Breast Cancer ' Compelling ' Data on New Agent in Pretreated Breast Cancer

Trastuzumab deruxtecan generated durable responses in HER2-positive metastatic breast cancer that had progressed on trastuzumab emtansine and other therapies in a phase 2 study.Medscape Medical News

Source: Medscape Hematology-Oncology Headlines - December 11, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news